No Data
Sumitomo Riko: Confirmation letter
Sumitomo Riko: Semi-Annual Report - Term 137 (2024/04/01 - 2025/03/31)
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
○ List of buying conversion brands Market Code Brand Name Closing Price SAR Tokyo Main Board <4527> Rohto Pharma 3443 3263 <4534> Mochida Pharma 3510 3355 <4536> Santen Pharma 1829 1733 <4552> JCR Pharma 6896 36 <4569> Kyorin Pharmaceuticals 1517 1468 <4574> Daiko Yakuhin 3903 73 <4611> Dainichi Paint 1026 1001 <4633> Sakata Inx
Stocks that moved the previous day part1 JBCC Holdings, EleMatec, LIXIL, etc.
Mitsui O.S.K. Lines <9104> closed at 5223 on the 31st, up 157. Financial estimates for the fiscal year ending March 2025 show a downward revision in operating profit, but upward revisions in revenue, operating profit, net profit, and dividends. In addition, a share buyback of up to 8.28% of the issued shares was announced. Sumitomo Chemical <5929> closed at 3926, up 267. Performance and dividend estimates for the fiscal year ending March 2025 were revised upward. Share buyback was also announced. Sumitomo Riko <5191> closed at 1572, up 84. Revenue estimates for the fiscal year ending March 2025 show a downward revision, but profit and dividend estimates were revised upward.
Active and newly established stocks in the afternoon session.
*Mitsui O.S.K. Lines ＜9104＞, 5,223 Operating profit for the fiscal year ending March 2025 is revised downward, but revenue, operating profit, net profit, and dividend estimates are revised upward. A share buyback of up to 8.28% of issued shares is also announced. *Sanwa HD ＜5929＞, 3,926 Performance and dividend estimates for the fiscal year ending March 2025 are revised upward. A share buyback is also announced. *Sumitomo Riko ＜5191＞, 1,572 Revenue estimate for the fiscal year ending March 2025 is revised downward, but profit and dividend estimates are revised upward. *JBCC Holdings
Sumitomo Riko: Differences between consolidated earnings forecasts for the second quarter (interim period) and actual values, revisions to full-year consolidated earnings forecasts, and revisions to surplus dividends (interim dividends/divi...
No Data
No Data